Evidence map›Paper›PMID 41079073›Full record

SynthesisFrontiers in oncology2025

Solitary fibrous tumor of the prostate: a case report and the systematic review of 74 published cases.

Hang Zhang, Chunyue Yan, Daowen Zhang, Zhipeng Chen, Kun Wang, Fan Zhou, Ming Yang, Fei Wang

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hang Zhang *Department of Radiology, Luzhou People's Hospital, Luzhou, China.
Chunyue Yan *Department of Emergency Medicine, Luzhou People's Hospital, Luzhou, China.
Daowen ZhangDepartment of Radiology, Luzhou People's Hospital, Luzhou, China.
Zhipeng ChenDepartment of Radiology, Luzhou People's Hospital, Luzhou, China.
Kun WangDepartment of Radiology, Luzhou People's Hospital, Luzhou, China.
Fan ZhouDepartment of Radiology, Luzhou People's Hospital, Luzhou, China.
Ming YangDepartment of Radiology, Luzhou People's Hospital, Luzhou, China.
Fei WangDepartment of Radiology, Luzhou People's Hospital, Luzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to report a rare case of solitary fibrous tumor of prostate (pSFT) and achieve the first systematic review of 74 published pSFT cases, and to integrate the end-to-end management of pSFT from preoperative diagnosis, treatment, and follow-up. Methods and case report: This study reports a additional case of pSFT. Subsequently, we performed a systematic review of PubMed, Web of Science, Cochrane Library, and Embase databases for potentially relevant articles on pSFT from inception of database to October 2024. Two researchers independently screened eligible literature, extracted data, and summarized data. Results: A 71-year-old male patient presented to our hospital with a three-month history of dysuria, and prostate-specific antigen (PSA) was within the normal range. After transurethral prostatectomy, the histopathological diagnosis was pSFT. During three years of outpatient follow-up, the patient had no recurrence. Ultimately, forty literatures were included with 74 cases of pSFT, and age ranged from 21 to 89 years (mean 57.5 years, median 61.5 years). There were 42 cases (56.8%) in North America, 22 cases (29.7%) in Asia, 9 cases (12.2%) in Europe, and 1 case (1.4%) in Oceania. The PSA values were within the normal range in almost all cases, and about 47.3% (35/74) cases underwent ultrasound, magnetic resonance imaging or CT examination before surgery. Notably, the most characteristic imaging biomarkers of the tumor were continuous and gradual enhancement from the periphery to the center with visible separation and capsule. The malignancy rate was 21.6% (16/74). There was no significant difference between benign and malignant pSFT of the lesion size (P > 0.05). Meanwhile, STAT6 and/or NAB2-STAT6 fusion genes were very sensitive biomarkers for pSFT. The median follow-up time of 38 patients with pSFT was 18 months (2-168 months), and the disease-free survival of benign, borderline and malignant pSFT was statistically significant (P=0.011). Conclusions: This study presents a new case and provides the first systematic review for 74 cases of pSFT, integrating clinical presentation, pathology, imaging, and follow-up data to assist surgeons in surgical planning. Surgical resection is the preferred treatment for pSFT, and regular follow-up is of vital importance. Due to the heterogeneity among current studies, future research may require standardized data reports and the establishment of a homogeneous public database to prepare for subsequent pSFT risk stratification studies. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251004804.

Indexed as

follow upprostateraresolitary fibrous tumorsystematic review

Identifiers

PMID41079073
PMCPMC12510860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.